MACROH2A1 and Huntington disease: Although direct targeting of H2AFY remains difficult, a histone deacetylase (HDAC) inhibitors, such as sodium phenylbutyrate (SPB), downregulated the expression of H2AFY mRNA in patients with Huntington’s disease (41).